Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.862
Buy
RSI(14)
78.171
Buy
STOCH(KDJ)(9,3,3)
72.866
Buy
ATR(14)
1.207
High Vlolatility
CCI(14)
157.331
Buy
Williams %R
13.441
Overbought
TRIX(12,20)
1.400
Sell
StochRSI(14)
100.000
Overbought
Greenwich Lifesciences Inc
GLSI13.365USD
+0.355+2.73%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
184.36MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Greenwich Lifesciences Inc
Currency: USD Updated: 2025-12-19Key Insights
Greenwich Lifesciences Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 122/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 42.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Greenwich Lifesciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
42.000
Target Price
+337.04%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Greenwich Lifesciences Inc Highlights
StrengthsRisks
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9-amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2) /neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. It has commenced a Phase III clinical trial, Flamingo-01, an immunotherapy to prevent breast cancer recurrences. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -8.85, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.44M shares, decreasing 11.03% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 624.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.04.
Financial Health
Currency: USD Updated: 2025-12-19The current financial score of Greenwich Lifesciences Inc is 6.92, ranking 193/404 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.83
Operational Efficiency
4.00
Growth Potential
6.75
Shareholder Returns
7.03
Greenwich Lifesciences Inc's Company Valuation
Currency: USD Updated: 2025-12-19The current valuation score of Greenwich Lifesciences Inc is 6.53, ranking 265/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is -8.85, which is -39.66% below the recent high of -5.34 and -287.72% above the recent low of -34.33.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 122/404
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-19The current earnings forecast score of Greenwich Lifesciences Inc is 8.00, ranking 168/404 in the Biotechnology & Medical Research industry. The average price target for Greenwich Lifesciences Inc is 42.00, with a high of 45.00 and a low of 39.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
42.000
Target Price
+337.04%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
534
Total
6
Median
6
Average
Company name
Ratings
Analysts
Greenwich Lifesciences Inc
GLSI
2
CRISPR Therapeutics AG
CRSP
30
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-19The current price momentum score of Greenwich Lifesciences Inc is 9.19, ranking 36/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 15.54 and the support level at 9.13, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
11.981
Buy
MA10
11.221
Buy
MA20
9.877
Buy
MA50
9.319
Buy
MA100
10.357
Buy
MA200
10.225
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-19The current institutional shareholding score of Greenwich Lifesciences Inc is 3.00, ranking 197/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 10.41%, representing a quarter-over-quarter decrease of 83.69%. The largest institutional shareholder is The Vanguard, holding a total of 282.18K shares, representing 2.04% of shares outstanding, with 0.96% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Patel (Snehal)
McWilliams (David B)
Hallock (Kenneth)
BlackRock Institutional Trust Company, N.A.
Rothe (Eric)
Thompson (Jaye L)
Geode Capital Management, L.L.C.
Daugherty (Frank Joseph)
DIM Funds SICAV S.A.
1
2
Risk Assessment
Currency: USD Updated: 2025-12-19No risk assessment score is currently available for Greenwich Lifesciences Inc. The Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 1.47. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.53
VaR
+6.58%
240-Day Maximum Drawdown
+43.16%
240-Day Volatility
+76.53%
Return
Best Daily Return
60 days
+15.36%
120 days
+15.36%
5 years
+38.98%
Worst Daily Return
60 days
-8.47%
120 days
-8.47%
5 years
-26.96%
Sharpe Ratio
60 days
+1.37
120 days
+1.48
5 years
+0.16
Risk Assessment
Maximum Drawdown
240 days
+43.16%
3 years
+61.65%
5 years
+86.68%
Return-to-Drawdown Ratio
240 days
-0.02
3 years
-0.19
5 years
-0.13
Skewness
240 days
+0.73
3 years
+1.09
5 years
+1.11
Volatility
Realised Volatility
240 days
+76.53%
5 years
+86.79%
Standardised True Range
240 days
+5.04%
5 years
+9.43%
Downside Risk-Adjusted Return
120 days
+307.07%
240 days
+307.07%
Maximum Daily Upside Volatility
60 days
+88.37%
Maximum Daily Downside Volatility
60 days
+38.00%
Liquidity
Average Turnover Rate
60 days
+0.41%
120 days
+0.51%
5 years
--
Turnover Deviation
20 days
+4.09%
60 days
+28.35%
120 days
+56.83%
Peer Comparison
Biotechnology & Medical Research
Greenwich Lifesciences Inc
GLSI
6.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
CRL
8.41 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.30 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Greenwich Lifesciences Inc?
The TradingKey Stock Score provides a comprehensive assessment of Greenwich Lifesciences Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Greenwich Lifesciences Inc’s performance and outlook.
How do we generate the financial health score of Greenwich Lifesciences Inc?
To generate the financial health score of Greenwich Lifesciences Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Greenwich Lifesciences Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Greenwich Lifesciences Inc.
How do we generate the company valuation score of Greenwich Lifesciences Inc?
To generate the company valuation score of Greenwich Lifesciences Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Greenwich Lifesciences Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Greenwich Lifesciences Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Greenwich Lifesciences Inc.
How do we generate the earnings forecast score of Greenwich Lifesciences Inc?
To calculate the earnings forecast score of Greenwich Lifesciences Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Greenwich Lifesciences Inc’s future.
How do we generate the price momentum score of Greenwich Lifesciences Inc?
When generating the price momentum score for Greenwich Lifesciences Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Greenwich Lifesciences Inc’s prices. A higher score indicates a more stable short-term price trend for Greenwich Lifesciences Inc.
How do we generate the institutional confidence score of Greenwich Lifesciences Inc?
To generate the institutional confidence score of Greenwich Lifesciences Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Greenwich Lifesciences Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Greenwich Lifesciences Inc.
How do we generate the risk management score of Greenwich Lifesciences Inc?
To assess the risk management score of Greenwich Lifesciences Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Greenwich Lifesciences Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Greenwich Lifesciences Inc.
